Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "B16 melanoma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
B16 melanoma is a murine tumor cell line used for research as a model for human skin cancers. B16 cells are useful models for the study of metastasis and solid tumor formation, and were one of the first effective murine tools for metastasis research.
Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor-draining LNs, maintaining Tregs in their normal suppressive phenotype when IDO was active, but allowing inflammation-induced conversion of Tregs to a polyfunctional T-helper phenotype similar to proinflammatory TH17 cells when IDO was blocked. In vitro, conversion of Tregs to the TH17-like phenotype was driven by antigen-activated effector T cells, and required IL-6 produced by activated pDCs. IDO regulated this conversion by dominantly suppressing production of IL-6 in pDCs, in a GCN2-kinase dependent fashion. In vivo, using a model of established B16 melanoma, the combination of an IDO-inhibitor drug plus anti-tumor vaccine caused upregulation of IL-6 in pDCs and in situ conversion of a majority of Tregs to the TH17 phenotype, with marked enhancement of CD8+ T cell activation and anti-tumor efficacy. Thus, Tregs in tumor-draining LNs can be actively re-programmed in vitro and in vivo into T-helper cells, without the need for physical depletion, and IDO serves as a key regulator of this critical conversion.
Owner:GEORGIA HEALTH SCI UNIV RES INST
Applicationof A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments
ActiveCN102218069APotent tumor suppressor activityBroad-spectrum tumor suppressor activityOrganic active ingredientsSteroidsTreatment effectMda mb 231
The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.
Owner:SHANGHAI AO QI MEDICAL TECH
Pharmaceutical composition and application thereof in preparing medicine for treating multidrug resistance of tumors
ActiveCN108159038AGood reversal of drug resistanceAvoid drug resistanceOrganic active ingredientsImmunoglobulinsPD-L1 inhibitorChlorogenic acid
The invention discloses a pharmaceutical composition and an application thereof in preparing a medicine for treating multidrug resistance of tumors and belongs to the field of biomedicines. The pharmaceutical composition is prepared from chlorogenic acid and tonka-bean quinic acid and can be used for preparing a reversal agent and a PD-1 / PD-L1 inhibitor for the multidrug resistance of the tumors.The pharmaceutical composition and the application disclosed by the invention have the beneficial effects that by combined use of the chlorogenic acid and the tonka-bean quinic acid, the synergistic interaction can be exerted, the drug-resistance reversal action on the tumor cell strain generating multidrug resistance for chemotherapeutic drugs and immunotherapeutic drugs is good, the expression of PD-1 / PD-L1 of tissues of transplanted tumors of mice with drug-resistant B16 melanoma and drug-resistant Lewis lung cancer can be effectively suppressed, and a role in proliferating CD4+T and CD8+Tcells of the mice with the drug-resistant B16 melanoma and the drug-resistant Lewis lung cancer can be effectively played.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Escherichia coli anti-tumor targeted engineering strain, and building method and application thereof
ActiveCN107574138AGood antitumor effectBacteriaPeptide/protein ingredientsEscherichia coliTumor target
Owner:HUNAN NORMAL UNIVERSITY
Anti-aging cosmetic composition capable of whitening and brightening skin
ActiveCN111265463AAvoid transportHigh activityCosmetic preparationsToilet preparationsHylocereus undatusCutin
The invention discloses an anti-aging cosmetic composition capable of whitening and brightening skin, which relates to the technical field of cosmetics. The anti-aging cosmetic composition capable ofwhitening and brightening the skin is prepared from retinol palmitate, wrapped retinol, a citrus peel extract, a yeast extract, a hylocereus undatus extract, carnosine, 3-o-ethyl ascorbic acid, saccharomycetes / rice fermentation product filtrate and wrapped ferulic acid. According to the invention, under the combined action of the matching of the components; the composition can absorb ultraviolet rays, resist oxidation, inhibit alpha-MSH from stimulating melanin synthesis of B16 melanoma cells, reduce melanin, inhibit tyrosinase activity, inhibit transport of melanin by driver protein, promoteactivation and renewal of epidermal cells, avoid abnormal cutin accumulation, increase skin gloss and remove dull yellow. The composition can also avoid various defects when being used independently,and the whitening efficiency is improved. The whitening and skin brightening effects are achieved through cooperation of the action principles of different components.
Owner:SHANGHAI NEW COGI COSMETIC
Skin lightening cosmetic compositions and methods
A cosmetic composition for topical application to skin is provided. The cosmetic composition includes vitamin B3 compound, a ricinoleate compound and a dermatologically acceptable carrier. The vitamin B3 compound and the ricinoleate beneficially or even synergistically up-regulate proteasomal protease activity as evidenced by a higher observed net luminescence value relative to the calculated net luminescence value in B16 melanoma cells.
Owner:THE PROCTER & GAMBLE COMPANY
Artocarpus hypargyreus hance extract and preparation method and application thereof
InactiveCN101766691APrevent agingTreat skin pigmentationCosmetic preparationsToilet preparationsDPPHWhitening Agents
The invention belongs to the technical fields of medicaments and foods and relates to an artocarpus hypargyreus hance extract and a preparation method and application thereof. In the artocarpus hypargyreus hance extract, the content of an isopentenyl-substituted flavonoid compound is 20 to 40 weight percent. The preparation method comprises the following steps; extracting stems and branches of artocarpus hypargyreus hance serving as a raw material by a solvent to prepare a total extract; dissolving the total extract in water, extracting with a halogenated solvent and an ester solvent in sequence; and taking an extraction phase of the ester solvent, and drying after reclaiming the solvent to obtain the artocarpus hypargyreus hance extract. Through activity tests such as tyrosinase in vitro, B16 melanoma cells, DPPH clearing and the like, results show that the artocarpus hypargyreus hance extract has strong effects of inhibiting the generation of the tyrosinase and melanin and clearing free radicals, can be used as a melanin inhibitor, a whitening agent or a natural antioxidant, and is applied to the fields of medicament, daily chemical engineering and food.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
Supernatant cultured by DCIK cell and use thereof
InactiveCN101333515AHave directHas an indirect killing effectPowder deliveryMammal material medical ingredientsAbnormal tissue growthSide effect
The invention relates to supernatant cultivated by DCIK cells and an application thereof. The supernatant and a preparation of freeze-dried powder prepared by frozen, dried and concentrated supernatant have good anti-tumor activity in tumor therapy. The supernatant cultivated by DCIK cells contains a series of mixtures of cytokines with biological activity which directly act on cell lines cultivated in vitro, thereby causing the forms of the cell lines such as mice melanoma B16 and THP-1 etc. to be affected and producing growth inhibition. The anti-tumor in vivo experiment shows that the supernatant cultivated by DCIK cells and the preparation of freeze-dried powder thereof can obviously inhibit the growth of the mouse melanoma B16 inoculated subcutaneously without obvious side effect. The invention fully proves the prospects of application and research of supernatant cultivated by DCIK cells, and paves the new way for the research of anti-tumor drugs.
Owner:SHANGHAI UNIV
Anti Toll-like receptor 2 antibody inhibiting tumor metastasis use
InactiveCN101147803AInhibit transferOrganic active ingredientsAntibody ingredientsLymphatic SpreadB16 melanoma
The present invention discloses an anti-TLP2 antibody. Said anti-TLR2 antibody can inhibit tumor, specially can inhibit the metastasis of B16 melanin tumor. Said anti-TLR2 antibody not only can block TLR2 activity, but also can obviously reduce number of metastatic foci of lung. At the same time, said invention finds that the bleomycin and said anti-TLR2 antibody have good synergistic action.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Application of sesquiterpenoids separated from Vernonia anthelmintica in preparation of medicaments for treating vitiligo
ActiveCN109939106AEasy to synthesizeOrganic active ingredientsOrganic chemistryMedicineVernonia anthelmintica
The invention relates to an application of sesquiterpenoids separated from Vernonia anthelmintica in preparation of medicaments for treating vitiligo. The sesquiterpenoids are obtained by separating and purifying Vernonia anthelmintica seeds and have three sesquiterpenoids, namely Vernodalin, Vernodanol D and vernodolinol, which can promote melanin synthesis. The effects of the three sesquiterpenoids on the melanin content of mouse B16 melanoma cells were investigated. The results showed that compound 1-3 could significantly increase the synthesis of the melanin under the effect of drug concentration without affecting the survival rate of the cells, and could be used as a lead compound for treating the vitiligo.
Owner:XINJIANG TECHN INST OF PHYSICS & CHEM CHINESE ACAD OF SCI
(S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
Owner:ONCONOX
Application of extractive and effective parts of datura flower in preparing medication for anti tumor
InactiveCN1958011AStrong anti-tumor effectAntineoplastic agentsPlant ingredientsMedicineWilms' tumor
Owner:卡南吉医药科技(上海)有限公司
Whitening and freckle-removing essence
PendingCN114522122APromote decompositionReduce depositionCosmetic preparationsToilet preparationsIrritationCytotoxicity
The invention discloses a whitening and freckle-removing essence and a preparation method of the whitening and freckle-removing essence. Comprising the following raw materials in parts by mass: 25 to 35 parts of a humectant, 2 to 3 parts of nicotinamide, 1 to 3 parts of nonapeptide-1, 2 to 3 parts of cystosella rubra extract, 2 to 4 parts of yeast extract, 2 to 3 parts of resveratrol, 0.5 to 1 part of 4-butylresorcinol, 0.3 to 0.5 part of hydrophilic colloid and 47.5 to 65.2 parts of deionized water. According to the whitening and freckle-removing essence disclosed by the invention, the 4-butylresorcinol has an inhibiting effect on generation of melanin, B16 melanoma cells synthesized by directly inhibiting the activity of tyrosinase and inhibiting the tyrosinase are not generated, and any cytotoxicity and irritation are not generated. Meanwhile, the added nonapeptide-1, resveratrol and yeast extract are whitening substances with very high biological activity, have the effects of whitening, brightening and fading spots, can accelerate melanin decomposition and reduce skin pigmentation, and have the effects of whitening and fading spots.
Owner:国妆(广州)科技有限公司
Construction of double-gene co-expression plasmid pEgr-IL18-B7.2 and application of double-gene co-expression plasmid pEgr-IL18-B7.2 to radiation-combined tumor resisting
InactiveCN105420262AImproving immunogenicityEnhance immune functionEnergy modified materialsGenetic material ingredientsLocal radiotherapyB16 melanoma
The invention provides construction of a double-gene co-expression plasmid pEgr-IL18-B7.2 and an application of the double-gene co-expression plasmid pEgr-IL18-B7.2 to radiation-combined tumor resisting. According to the tumor gene-radiotherapy theory and the radiation induction expression characteristics of Egr-1 genes, the double-gene co-expression plasmid pEgr-IL18-B7.2 is constructed on the basis of B7.2 genes of a clone mouse. IL18 genes with the anti-tumor effect and costimulatory-molecule B7-2 genes are transferred into tumor cells through double-gene carriers; the construction and the application further prove that low-dosage radiation can induce radiation-sensitive promoters, and therefore the finer-control effect is achieved on multi-gene expression; radiation-induced double-gene expression shows a certain time-interval and dose-effect rule. According to a test, the constructed double-gene plasmid is further injected into a tumor body of a B16 melanoma transplanted to the mouse, local radiotherapy is carried out in cooperation, and the tumor inhibiting effect more remarkable than that of pure radiotherapy is shown, and preliminary discussion is made for possible mechanisms in the immunology aspect.
Owner:JILIN UNIV
Skin lightening cosmetic compositions and methods
Owner:PROCTER & GAMBLE CO
Compositions and Methods for Treatment of Cancer
Here we show that SEG / SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG / SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFNγ serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNFα levels above baseline levels. Presentation of the SEG / SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFNγ levels absent toxic levels of TNFα.
Owner:TERMAN DAVID S +1
Compositions and methods for treatment of cancer
Here we show that SEG / SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG / SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFNγ serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNFα levels above baseline levels. Presentation of the SEG / SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFNγ levels absent toxic levels of TNFα.
Owner:TERMAN DAVID S +1
(s,r.)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as Anti-cancer and antiviral agent
The present invention relates to an isoxazole derivative, the compound of formula (I)herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027.Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1 / 2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL / 6 mice implanted with B16 melanoma.
Owner:ONCONOX
High-temperature-resistant mutant SOD with PTD and encoding gene and application thereof
ActiveCN110872581AImprove activity stabilityImprove thermal stabilityCosmetic preparationsPeptide/protein ingredientsFood additiveMutated protein
The invention discloses a PTD-SOD-MUTANT protein which is a fusion protein composed of a protein transduction structural domain PTD and SOD derived from thermophilic bacteria HB27, wherein I27L and D107A double mutation occurs in an SOD amino acid sequence. The PTD-SOD-MUTANT protein has the advantages of being good in thermal stability, high in activity and capable of penetrating through cell membranes to enter cells and the like. In-vitro and in-vivo experiments show that the protein has a very strong proliferation inhibition effect on mouse B16 melanoma cells and mouse malignant melanoma, and the protein and adriamycin (DOX) have a synergistic interaction effect on tumor cells. The PTD-SOD-MUTANT protein can be used as a pharmaceutical composition, a cosmetic active component, a food additive and the like, and has a great application value and wide application prospect in the fields of drug research and development, daily necessities, foods and the like.
Owner:SUZHOU UNIV +2
Uighur medicine compound for leucoderma and preparation method thereof
PendingCN107569532ADefinite curative effectPromote formationSolution deliveryPill deliveryHard CapsuleSolvent
The invention relates to a Uighur medicine compound for leucoderma and a preparation method thereof. The compound is prepared from the following medicinal materials: herb of carum carvi, fructus psoraleae, puncture vine caltrop fruit, seed of ajowan-caraway, root of operculina turpethum; oral dosage forms such as oral liquid, syrup, granules, hard capsules and tablets are prepared by the methods of solvent extraction, impurity removal, concentration and drying and by adopting proper accessories. According to the Uighur medicine compound and the preparation method thereof provided by the invention, the Uighur medicine compound for leucoderma is prepared by a modern extraction method according to the theory of Uighur medicine and in combination with the characteristics of national medicinesand long-term civil clinical practice, the efficacy is enhanced, and the bioavailability is improved. In-vitro activity experiments indicate that different dosage forms of the Uighur medicine compoundfor leucoderma prepared by the method influence the morphology of mouse B16 melanoma cells to different degrees and realize a concentration dependence activation effect on the cell activity and the melanin synthetic quantity. Experimental results indicate that different dosage forms of the Uighur medicine compound for leucoderma all show very strong ability of activating B16 melanoma cells and promoting melanin formation and can be used for treating leucoderma.
Owner:XINJIANG TECHN INST OF PHYSICS & CHEM CHINESE ACAD OF SCI
Composition with whitening and acne-removing effects and its preparation method and application
ActiveCN108158888BGood whitening effectSignificant anti-acne effectCosmetic preparationsToilet preparationsTyrosinePropionibacterium
Owner:INFINITUS (CHINA) CO LTD
Application of peach blossom blood purifying pill compound preparation to preparation of drugs for curing chloasma and freckles
InactiveCN108743691ANo obvious side effectsHigh clinical application valuePill deliveryDermatological disorderDiseaseTyramine oxidase
The invention discloses a new application of a peach blossom blood purifying pill compound preparation to preparation of drugs for curing chloasma and freckles. The experiment proves that the peach blossom blood purifying pill preparation can obviously inhibit synthesis of melanin of mouse B16 melanoma cells, while has no effect on the activation of tyramine oxidase, and the peach blossom blood purifying pill preparation has the good effect on treatment of pigmented dermatoses can be proved. Clinical research verifies that the peach blossom blood purifying pill preparation adopts vitamin E asa control group when being used for treating chloasma, the effect of the peach blossom blood purifying pill preparation on treating chloasma is obviously superior to the effect of taking vitamin drugsorally, and the peach blossom blood purifying pill preparation has the better safety. The clinic research verifies that when the peach blossom blood purifying pill preparation is used for treating freckles, oral taking vitamin E and externally applying hydroquinone are taken as the control group, the total effective rate is improved remarkably, and no obvious adverse drug reaction occurs. The above research proves that the application field of the peach blossom blood purifying pill to treatment of chloasma and freckles is developed, the new treatment drug is provided for the field of chloasmaand freckle skin diseases, and the peach blossom blood purifying pill compound preparation has the very good clinic research meaning.
Owner:山东新宝医药有限公司
A kind of laurel wood extract and its preparation method and application
The invention belongs to the technical fields of medicaments and foods and relates to an artocarpus hypargyreus hance extract and a preparation method and application thereof. In the artocarpus hypargyreus hance extract, the content of an isopentenyl-substituted flavonoid compound is 20 to 40 weight percent. The preparation method comprises the following steps; extracting stems and branches of artocarpus hypargyreus hance serving as a raw material by a solvent to prepare a total extract; dissolving the total extract in water, extracting with a halogenated solvent and an ester solvent in sequence; and taking an extraction phase of the ester solvent, and drying after reclaiming the solvent to obtain the artocarpus hypargyreus hance extract. Through activity tests such as tyrosinase in vitro, B16 melanoma cells, DPPH clearing and the like, results show that the artocarpus hypargyreus hance extract has strong effects of inhibiting the generation of the tyrosinase and melanin and clearing free radicals, can be used as a melanin inhibitor, a whitening agent or a natural antioxidant, and is applied to the fields of medicament, daily chemical engineering and food.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
Application of pumpkin protein in the preparation of drugs for the treatment of lung cancer
InactiveCN101843894BGood anti-solid tumor effect in vivo and in vitroReduce inhibitionPeptide/protein ingredientsRespiratory disorderRibosome-inactivating proteinB16 melanoma
The application of pumpkin protein in pharmacy can isolate a ribosome inactivating protein-pumpkin protein from pumpkin pulp, and the protein shows good antitumor activity and can be used to prepare antitumor drugs. Pumpkin protein can significantly inhibit gastric cancer cells SGC7901 cultured in vitro, liver cancer cells HepG2, Bel7404, non-small cell lung cancer cells A549, breast cancer cells MCF-7 and melanoma cells B16, while inhibiting human normal liver cells and peripheral blood lymphocytes. The effect is small, showing obvious selectivity; pumpkin protein can also significantly inhibit cervical cancer U14, melanoma B16 and lung cancer Lewis and other animal transplanted tumors in mice. In addition, the present invention also confirms that the apoptosis-inducing and differentiation-inducing effect of pumpkin protein on tumor cells is an important mechanism of its anti-tumor activity.
Owner:FUJIAN INST OF RES ON THE STRUCTURE OF MATTER CHINESE ACAD OF SCI +1
Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance
PendingUS20210085630A1Good effectAddressing drug resistanceOrganic active ingredientsImmunoglobulinsChlorogenic acidStage melanoma
A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1 / PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1 / PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.
Owner:SICHUAN JIUZHANG BIO TECH CO LTD
Composition with whitening and acne-removing effects as well as preparation method and application of composition
ActiveCN108158888AGood whitening effectSignificant anti-acne effectCosmetic preparationsToilet preparationsCurative effectMelanin synthesis
The invention relates to the technical field of health-care food, in particular to a composition with whitening and acne-removing effects as well as a preparation method and application of the composition. According to the composition, medicinal and edible raw materials such as radix puerariae, radix platycodi, liquorice root, radix angelicae dahuricae and fructus momordicae are compounded according to specific proportions; the experiment shows that the composition provided by the invention has a significant inhibitory effect on melanin synthesis of B16 melanoma cells and activity of tyrosinase, can remarkably improve the ultraviolet-induced skin pigmentation of mice and has an obvious inhibitory effect on acne pathogenic bacteria such as propionibacterium, staphylococcus epidermidis and staphylococcus aureus; in addition, the composition has an obvious curative effect on rabbit ear acne. The results show that the composition disclosed by the invention has remarkable whitening and acne-removing effects.
Owner:INFINITUS (CHINA) CO LTD
Anti Toll-like receptor 2 antibody inhibiting tumor metastasis use
InactiveCN101147803BInhibit transferOrganic active ingredientsAntibody ingredientsToll-like receptorB16 melanoma
The present invention discloses an anti-TLP2 antibody. Said anti-TLR2 antibody can inhibit tumor, specially can inhibit the metastasis of B16 melanin tumor. Said anti-TLR2 antibody not only can block TLR2 activity, but also can obviously reduce number of metastatic foci of lung. At the same time, said invention finds that the bleomycin and said anti-TLR2 antibody have good synergistic action.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Active parts of Viola tianshan and its application in the preparation of whitening cosmetics
The invention relates to the application of plant extracts in the field of cosmetics with whitening effect, and discloses the application of active parts of Viola tianshanensis in the field of cosmetics with whitening effect. The preparation method of this active part is to take the dry powder of Viola tianshanensis whole plant, extract with ethanol, combine the filtrates, recover the solvent under reduced pressure, and obtain the crude extract of Viola tianshanensis; Extract with n-butanol in sequence, collect, and evaporate to dryness to obtain the active part of Viola tianshanensis. The ethyl acetate and n-butanol fraction of Viola tianshan obtained by the above method is a natural plant extract that has the effect of inhibiting tyrosinase and B16 melanocytes. It has no side effects on the human body and can be used to prepare whitening products. cosmetics.
Owner:王琪
A high temperature resistant mutant sod with ptd and its application
ActiveCN110872581BImprove activity stabilityImprove thermal stabilityCosmetic preparationsPeptide/protein ingredientsFood additiveStage melanoma
The invention discloses a PTD-SOD-MUTANT protein, which is a fusion protein composed of a protein transduction domain PTD and SOD derived from thermophilic bacteria HB27, wherein the SOD amino acid sequence has double mutations of I28L and D108A. PTD‑SOD‑MUTANT protein has the advantages of good thermal stability, high activity, and can enter cells through cell membranes. In vitro and in vivo experiments show that this protein has a strong inhibitory effect on the proliferation of mouse B16 melanoma cells and mouse malignant melanoma. The combination of this protein and doxorubicin (DOX) has a synergistic effect on tumor cells. PTD‑SOD‑MUTANT proteins can be used as pharmaceutical compositions, cosmetic active components, food additives, etc., and have great application value and broad application prospects in the field of drug research and development, daily necessities, and food.
Owner:SUZHOU UNIV +2
Applicationof A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments
ActiveCN102218069BGrowth inhibitionLow toxicityOrganic active ingredientsSteroidsMda mb 231Therapeutic effect
The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.
Owner:SHANGHAI AO QI MEDICAL TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com